INO had a R/S and did well, look at LJPC.
The issue is when to do it. they would need to do it when good news is about to hit
I just received the nice postcard from ONCS thanking shareholders, now how about really thanking us by showing some confidence in your company and buy some damn shares?
I was considering buying some CNAT this week but at these prices I'm now thinking about adding more IDRA. Not much money for me to play with so it has to be only one of them
I remember seeing a European indication study in Phase 3 on their website some time ago and now it's not there. Anyone have any idea about this? I emailed them and received no response.
I was going to either buy 1,000 shares of CYTR or another 1,000 shares of SYN at $3.00 and I chose to buy SYN.
Obviously not looking like a good move right now but hopefully in a few weeks I will be thinking otherwise
Notice how many times he mentions non dilutive funding.
Synthetic Biologics is positioned to achieve a number of important milestones during 2015, each one key to advancing us toward FDA registration trials for SYN-004 and SYN-010, non-dilutive funding for SYN-005 and partnering arrangements for Trimesta.
With regard to our SYN-004 C. difficile program, topline data is anticipated to be reported from the recently initiated Phase 2a clinical trial during 2Q 2015. Initiation of a Phase 2b proof-of-concept clinical trial is planned during 2H 2015, with topline data expected in 2H 2015.
For our SYN-010 IBS-C program, submission of an Investigational New Drug (IND) application to initiate clinical trials is expected in 1H 2015. Initiation of Phase 2 clinical trials is planned for 2Q 2015, with topline data expected in 2H 2015.
We continue discussions to secure non-dilutive funding to support preclinical and clinical development efforts for our SYN-005 Pertussis program.
And, in our Trimesta MS program, MRI brain scan analyses are underway by the lead investigator to evaluate changes in the brain that correlate with improvements seen in clinical outcomes, with topline data expected from the lead investigator during 1H 2015. Active discussions with a number of groups are ongoing, and a strategic partnership to further the clinical development of Trimesta is anticipated during 2Q 2015.
I would like to again thank our employees for their dedicated work, our clinical advisors for their valuable expertise in our areas of pursuit, our loyal shareholders for their support of our programs and goals, and our collaborators for their scientific prowess and keen clinical insights.
We look forward to reporting our progress to you during what promises to be a very eventful year for Synthetic Biologics.
Sentiment: Strong Buy
I don't know, I see a few purchases here:
Apr 1, 2015 ZEIN YOUSSEF EL
3,075 Direct Acquisition (Non Open Market) at $3.52 per share. 10,824
Apr 1, 2015 GERAGHTY JAMES A
3,000 Direct Acquisition (Non Open Market) at $3.52 per share. 10,560
Apr 1, 2015 BAKER JULIAN
16,410 Indirect Acquisition (Non Open Market) at $3.52 per share. 57,763
Mar 17, 2015 ZEIN YOUSSEF EL
1,250 Direct Option Exercise at $4.80 per share. 6,000
Feb 13, 2015 BAKER JULIAN
5,333,333 Indirect Purchase at $3.75 per share. 19,999,998
Jan 2, 2015 BAKER JULIAN
11,781 Indirect Acquisition (Non Open Market) at $4.90 per share. 57,726
Sentiment: Strong Buy